• Kura Oncology released an announcement on updated long-term Phase 1a FIT-001 data for darlifarnib with cabozantinib in advanced clear cell renal cell carcinoma.
• Data will be presented in an oral session at the Kidney Cancer Research Summit on July 24, 2026.
• A randomized Phase 1b study comparing the combination with cabozantinib alone remains ongoing to support Phase 3 dose selection.
• Kura scheduled a virtual investor call for July 27, 2026, with webcast details at www.kuraoncology.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.